Haitao Ju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haitao Ju has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Lehui Li
School of Public Health, Inner Mongolia Medical University, 010110 Hohhot, Inner Mongolia, China
1 shared publication - Nan Zhang
School of Public Health, Inner Mongolia Medical University, Hohhot, China
1 shared publication - Ning Cao
School of Public Health, Inner Mongolia Medical University, 010110 Hohhot, Inner Mongolia, China
1 shared publication - Tao Yan
School of Public Health, Inner Mongolia Medical University, 010110 Hohhot, Inner Mongolia, China
1 shared publication - Xingguang Zhang
School of Public Health, Inner Mongolia Medical University, Hohhot, China
1 shared publication Yuan Shen
School of Public Health, Inner Mongolia Medical University, 010110 Hohhot, Inner Mongolia, China
1 shared publication
Latest Publications
- Open Access
- 27 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5) , 36363
Low-Density Lipoprotein Cholesterol Reductions of not Less Than 60 mg/dL Prevent Hemorrhagic Stroke in Hypertensive Populations: A Meta-analysis
Background: The association between low-density lipoprotein cholesterol (LDL-C) levels and the risk of hemorrhagic stroke (HS) detected through different blood pressure statuses remains unclear. Hence, we systematically evaluated the association between LDL-C and HS in populations with and without hypertension. Methods: We searched PubMed, Cochrane Library, and Embase databases for articles written in English. Only prospective design or randomized controlled trials (RCTs) reporting effect estimates with 95% confidence intervals (CIs) for the relationship between LDL-C and HS were included. We pooled risk ratios (RRs) stratified by blood pressure status and dose–response analyses with a two-stage generalized least squares for trend estimation (GLST) model. Finally, we compared the lower and optimal groups to find the effect of very low LDL-C levels on the risk of HS. Results: We included seven randomized controlled trials and 9 prospective cohort studies involving 304,763 participants with 2125 (0.70%) HS events. The non-linear trend suggested that LDL-C levels of approximately 80 mg/dL among hypertensive patients and 115 mg/dL among non-hypertensive patients had the lowest risk of HS. Meanwhile, continually lowering LDL-C levels under the optimal (80 mg/dL for hypertensive patients and 115 mg/dL for non- hypertensive patients) LDL-C level would increase the risk of HS in the hypertensive population (RR = 1.84, 95% CI: 1.36–2.50) but not in the non-hypertensive population (RR = 1.15, 95% CI: 0.97–1.36). Conclusions: The risk of HS can be effectively reduced by controlling LDL-C levels to 60–80 mg/dL in the hypertensive population and 115 mg/dL in the non-hypertensive population. The safety range of controlling LDL-C levels to protect against HS among hypertensive patients is narrower than that among the non-hypertensive population. Additionally, controlling blood pressure might play a positive role in safeguarding against HS by lowering LDL-C levels.
- 27 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5) , 36363
Open AccessLow-Density Lipoprotein Cholesterol Reductions of not Less Than 60 mg/dL Prevent Hemorrhagic Stroke in Hypertensive Populations: A Meta-analysis
Background: The association between low-density lipoprotein cholesterol (LDL-C) levels and the risk of hemorrhagic stroke (HS) detected through different blood pressure statuses remains unclear. Hence, we systematically evaluated the association between LDL-C and HS in populations with and without hypertension. Methods: We searched PubMed, Cochrane Library, and Embase databases for articles written in English. Only prospective design or randomized controlled trials (RCTs) reporting effect estimates with 95% confidence intervals (CIs) for the relationship between LDL-C and HS were included. We pooled risk ratios (RRs) stratified by blood pressure status and dose–response analyses with a two-stage generalized least squares for trend estimation (GLST) model. Finally, we compared the lower and optimal groups to find the effect of very low LDL-C levels on the risk of HS. Results: We included seven randomized controlled trials and 9 prospective cohort studies involving 304,763 participants with 2125 (0.70%) HS events. The non-linear trend suggested that LDL-C levels of approximately 80 mg/dL among hypertensive patients and 115 mg/dL among non-hypertensive patients had the lowest risk of HS. Meanwhile, continually lowering LDL-C levels under the optimal (80 mg/dL for hypertensive patients and 115 mg/dL for non- hypertensive patients) LDL-C level would increase the risk of HS in the hypertensive population (RR = 1.84, 95% CI: 1.36–2.50) but not in the non-hypertensive population (RR = 1.15, 95% CI: 0.97–1.36). Conclusions: The risk of HS can be effectively reduced by controlling LDL-C levels to 60–80 mg/dL in the hypertensive population and 115 mg/dL in the non-hypertensive population. The safety range of controlling LDL-C levels to protect against HS among hypertensive patients is narrower than that among the non-hypertensive population. Additionally, controlling blood pressure might play a positive role in safeguarding against HS by lowering LDL-C levels.